Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients. (2020)

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41397-019-0139-4

PubMed Identifier: 31819160

Publication URI: http://europepmc.org/abstract/MED/31819160

Type: Journal Article/Review

Volume: 20

Parent Publication: The pharmacogenomics journal

Issue: 3

ISSN: 1470-269X